Emergent BioSolutions (EBS) Net Income towards Common Stockholders Growth (5y) (2016 - 2026)
Emergent BioSolutions (EBS) Net Income towards Common Stockholders Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -110.34% |
| Mar 31, 2026 | -37.22% |
| Dec 31, 2025 | -18.06% |
| Sep 30, 2025 | 5.33% |
| Jun 30, 2025 | -16.32% |
| Mar 31, 2025 | 49.39% |
| Dec 31, 2024 | -21.68% |
| Sep 30, 2024 | 21.59% |
| Jun 30, 2024 | -97.17% |
| Mar 31, 2024 | 18.60% |
| Dec 31, 2023 | -69.87% |
| Sep 30, 2023 | -70.96% |
| Jun 30, 2023 | -48.48% |
| Mar 31, 2023 | -106.99% |
| Dec 31, 2021 | 103.46% |
| Sep 30, 2021 | -105.16% |
| Jun 30, 2021 | 20.27% |
| Mar 31, 2021 | 61.02% |
| Dec 31, 2020 | 86.15% |
| Sep 30, 2020 | 57.45% |